Thus, low expression of fDEGs, of genes of the invasive gene regulatory network, and of genes of EGFR-EMT-dependent 5-gene prognostic signature was associated with reduced response to Cetuximab in R/M-HNSCC patients. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.